Last reviewed · How we verify
Glulisine
At a glance
| Generic name | Glulisine |
|---|---|
| Also known as | Apidra, apidra |
| Sponsor | Emory University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal. (PHASE4)
- Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients (PHASE3)
- Afrezza® INHALE-1 Study in Pediatrics (PHASE3)
- Degludec Glargine U300 Hospital Study (NA)
- Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) (PHASE4)
- Closed Loop From Onset in Type 1 Diabetes (NA)
- Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes (PHASE4)
- Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glulisine CI brief — competitive landscape report
- Glulisine updates RSS · CI watch RSS
- Emory University portfolio CI